Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Relay Therapeutics Inc’s stock clocked out at $3.66, up 5.48% from its previous closing price of $3.47. In other words, the price has increased by $5.48 from its previous closing price. On the day, 2.09 million shares were traded. RLAY stock price reached its highest trading level at $3.67 during the session, while it also had its lowest trading level at $3.38.
Ratios:
To gain a deeper understanding of RLAY’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.95 and its Current Ratio is at 15.95. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on September 10, 2024, Upgraded its rating to Buy and sets its target price to $16 from $10.60 previously.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 11 ’25 when Patel Sanjiv sold 140,182 shares for $3.85 per share. The transaction valued at 539,701 led to the insider holds 625,948 shares of the business.
Patel Sanjiv sold 75,324 shares of RLAY for $278,699 on Feb 13 ’25. The President and CEO now owns 883,089 shares after completing the transaction at $3.70 per share. On Jan 29 ’25, another insider, Rahmer Peter, who serves as the insider of the company, sold 26,541 shares for $4.55 each. As a result, the insider received 120,762 and left with 419,681 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 620450560 and an Enterprise Value of -144580176. For the stock, the TTM Price-to-Sale (P/S) ratio is 61.98 while its Price-to-Book (P/B) ratio in mrq is 0.79. Its current Enterprise Value per Revenue stands at -14.448 whereas that against EBITDA is 0.38.
Stock Price History:
The Beta on a monthly basis for RLAY is 1.55, which has changed by -0.5520196 over the last 52 weeks, in comparison to a change of 0.087141395 over the same period for the S&P500. Over the past 52 weeks, RLAY has reached a high of $10.72, while it has fallen to a 52-week low of $3.02. The 50-Day Moving Average of the stock is -11.59%, while the 200-Day Moving Average is calculated to be -38.74%.
Shares Statistics:
It appears that RLAY traded 2.22M shares on average per day over the past three months and 2597800 shares per day over the past ten days. A total of 167.76M shares are outstanding, with a floating share count of 127.17M. Insiders hold about 24.99% of the company’s shares, while institutions hold 75.24% stake in the company. Shares short for RLAY as of 1740700800 were 16188685 with a Short Ratio of 7.28, compared to 1738281600 on 15660482. Therefore, it implies a Short% of Shares Outstanding of 16188685 and a Short% of Float of 11.55.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
